A Mab A Case Study In Bioprocess Development

The A-Mab Case Study is a seminal 2009 document developed by the CMC-Biotech Working Group—a consortium including Amgen, Genentech, and Pfizer—to demonstrate how Quality by Design (QbD) principles can be applied to monoclonal antibody (mAb) bioprocessing. It serves as a practical roadmap for implementing International Council for Harmonisation (ICH) guidelines Q8(R2), Q9, and Q10 in a biotechnology environment. Core Framework of the A-Mab Study

3. Downstream Processing (DSP) Development

3.1 Harvest & Clarification

• Primary recovery: Centrifugation (disk-stack, 10,000 ×g) + depth filtration (Pall Supracap 60).
• Yield: 92%, turbidity < 10 NTU.

Final Fed-Batch Process:

4. Analytical & Formulation Challenges

• Aggregation: Identified low pH during Protein A elution as cause. Mitigation: reduced hold time, added 200 mM arginine in elution buffer.
• Charge variants: CEX resolved acidic variants; later mapped to deamidation (Asn-55). Controlled by limiting bioreactor pH drift.
• Forced degradation studies: mAb stable for 24 months at 2–8°C; no significant fragmentation.

Once the mAb is produced, it must be isolated and purified from the cell culture. Contentstack A–Mab: A Case Study in Bioprocess Development - ISPE 30 Oct 2009 — A Mab A Case Study In Bioprocess Development

Title: From Gene to GMP: A Case Study in Monoclonal Antibody (mAb) Bioprocess Development

1. Introduction: The mAb Challenge

Monoclonal antibodies (mAbs) represent the gold standard of biopharmaceuticals, but their development is fraught with risk. For a novel IgG1 targeting an autoimmune disease, the goal was aggressive: transition from DNA sequence to a stable, high-yield (>5 g/L) process suitable for Phase I clinical trials within 12 months. The A-Mab Case Study is a seminal 2009

The Intervention: The development team shifts from a traditional batch process to a fed-batch process with a chemically defined, animal-component-free medium. Using Design of Experiments (DoE), they optimize the feed strategy: Final Fed-Batch Process: 4

Critical Quality Attributes (CQAs): Identifying product attributes (e.g., glycosylation, aggregation, deamidation) that impact clinical performance.